Holen Sie sich die Stockscreener-App
51.81
1.44%
0.735
Handel nachbörslich:
52.84
1.03
+1.99%
Schlusskurs vom Vortag:
$51.08
Offen:
$52.42
24-Stunden-Volumen:
50,386
Relative Volume:
0.85
Marktkapitalisierung:
$142.60M
Einnahmen:
$697.00K
Nettoeinkommen (Verlust:
$-38.97M
KGV:
-1.7819
EPS:
-29.075
Netto-Cashflow:
$-33.33M
1W Leistung:
+7.38%
1M Leistung:
-4.71%
6M Leistung:
-52.90%
1J Leistung:
-90.34%
1-Tages-Spanne:
$51.10
$54.05
1-Wochen-Bereich:
$49.00
$55.32
52-Wochen-Spanne:
$7.26
$543.38
Spruce Biosciences Inc Stock (SPRB) Company Profile
Firmenname
Spruce Biosciences Inc
Sektor
Branche
Telefon
(415) 655-4168
Adresse
611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO
Compare SPRB vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SPRB
Spruce Biosciences Inc
|
51.81 | 140.57M | 697.00K | -38.97M | -33.33M | -29.07 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Spruce Biosciences Inc Stock (SPRB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-27 | Eingeleitet | Craig Hallum | Buy |
| 2025-12-23 | Eingeleitet | Oppenheimer | Outperform |
| 2025-12-03 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-10-28 | Hochstufung | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-12-11 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-12-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-03-14 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-03-14 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-03-14 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-14 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-03-14 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-21 | Eingeleitet | Guggenheim | Buy |
| 2021-12-17 | Eingeleitet | Oppenheimer | Outperform |
| 2021-12-10 | Eingeleitet | The Benchmark Company | Speculative Buy |
| 2021-11-16 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-07-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-11-03 | Eingeleitet | Cowen | Outperform |
| 2020-11-03 | Eingeleitet | Credit Suisse | Outperform |
| 2020-11-03 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-11-03 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Spruce Biosciences Inc Aktie (SPRB) Neueste Nachrichten
Spruce Biosciences (SPRB) director granted 1,700 stock options at 52.70 - Stock Titan
Spruce Biosciences (SPRB) chair receives grant of 1,700 stock options - Stock Titan
Spruce Biosciences (NASDAQ: SPRB) grants director 1,700 options - Stock Titan
Spruce Biosciences (SPRB) grants director Keli Walbert 1,700 options - Stock Titan
Spruce Biosciences (SPRB) 2026 annual meeting and say-on-pay votes - Stock Titan
Here's Why Pulse Biosciences, Inc (PLSE) is a Great Momentum Stock to Buy - Yahoo Finance
Spruce Biosciences Inc (SPRB) Stock Price, Quote, News & History - Benzinga
SPRB: Directors elected, all proposals approved, and strategic plans funded for regulatory milestones - TradingView
SPRB: All proposals passed, with updates on financing, manufacturing, and regulatory milestones shared - TradingView
Wall Street Analysts Believe Spruce Biosciences (SPRB) Could Rally 181.21%: Here's is How to Trade - MSN
Is Spruce Biosciences (SPRB) Overvalued After Q1 2026 EPS Beat? - GuruFocus
Citadel entities, Kenneth Griffin hold ~5.1% of Spruce Biosciences (SPRB) - Stock Titan
Alyeska Group (SPRB) discloses 61,670-share position, 4.49% of float - Stock Titan
Leerink Partners Maintains Spruce Biosciences(SPRB.US) With Buy Rating, Cuts Target Price to $120 - Moomoo
Squadron entities report 12,200 SPRB shares (0.9%) — SPRB - Stock Titan
Wellington Group discloses 48,796 shared dispositive shares in Spruce Biosciences (NASDAQ: SPRB) - Stock Titan
SPRB Maintains by Citizens -- Price Target Lowered to $150 - GuruFocus
Spruce Biosciences 1Q Research and Development Expenses $7.6M >SPRB - Moomoo
Spruce Biosciences, Inc. Stock 12‑Month Price Target Cut to $178.6, Implies 210% Upside - TradingView
Spruce Biosciences Is Maintained at Market Outperform by Citizens - Moomoo
Spruce Biosciences price target lowered to $150 from $170 at Citizens - TipRanks
Citizens lowers Spruce Biosciences stock price target on model update By Investing.com - Investing.com Nigeria
Citizens lowers Spruce Biosciences stock price target on model update - Investing.com
Spruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates - BioSpace
Spruce Biosciences (NASDAQ: SPRB) posts Q1 loss and bolsters cash - Stock Titan
Spruce Biosciences (SPRB) Progresses Towards Key Regulatory Mile - GuruFocus
Spruce Biosciences reports Q1 EPS ($8.94), consensus ($6.11) - TipRanks
Spruce Biosciences, Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Spruce Biosciences Reports Q1 2026 Financials, Advances TA-ERT Toward FDA Approval for MPS IIIB, and Strengthens Leadership Team - Minichart
Spruce Biosciences reports Q1 2026 loss of $12.3M, cash $54.1M and $107.3M preliminary April balance - TradingView
Spruce Biosciences (SPRB) boosts cash with $69M raise, funds TA‑ERT into 2027 - Stock Titan
TradingKey - TradingKey
Ikarian Capital, Neil Shahrestani file ownership of 121,356 SPRB shares (4.8%) - Stock Titan
SPRB Stock Price, Quote & Chart | SPRUCE BIOSCIENCES INC (NASDAQ:SPRB) - ChartMill
Sagimet Biosciences Inc. (SGMT) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Spruce Biosciences appoints two commercial executives By Investing.com - Investing.com Australia
Spruce Biosciences Expands Leadership Team - Contract Pharma
Spruce Biosciences Adds Two Senior Commercial Executives as It Prepares Rare Disease Launch Strategy - citybiz
Spruce Biosciences appoints two commercial executives - Investing.com
Spruce Biosciences further strengthens its commercial leadership team with the appointments of Brian Walls as vice president, market access and Darren Johnson as vice president, commercial operations - marketscreener.com
Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations - ChartMill
SPRB Technical Analysis | Trend, Signals & Chart Patterns | SPRUCE BIOSCIENCES INC (NASDAQ:SPRB) - ChartMill
ExodusPoint entities file Schedule 13G on SPRB (SPRB) - Stock Titan
Spruce Biosciences (SPRB) Projected to Post Earnings on Tuesday - MarketBeat
SPRB Initiated Coverage by Craig-Hallum -- Rating Set to Buy - GuruFocus
Craig-Hallum initiates Spruce Biosciences stock with buy rating By Investing.com - Investing.com South Africa
Craig-Hallum initiates Spruce Biosciences stock with buy rating - Investing.com
Finanzdaten der Spruce Biosciences Inc-Aktie (SPRB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Spruce Biosciences Inc-Aktie (SPRB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Gharib Samir M. | PRESIDENT AND CFO |
Dec 15 '25 |
Option Exercise |
0.00 |
1,009 |
0 |
8,447 |
| Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER |
Dec 15 '25 |
Option Exercise |
0.00 |
2,676 |
0 |
14,922 |
| Gharib Samir M. | PRESIDENT AND CFO |
Dec 11 '25 |
Option Exercise |
0.00 |
1,900 |
0 |
8,296 |
| Gharib Samir M. | PRESIDENT AND CFO |
Dec 10 '25 |
Option Exercise |
0.00 |
514 |
0 |
6,580 |
| Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER |
Dec 11 '25 |
Option Exercise |
0.00 |
4,950 |
0 |
15,192 |
| Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER |
Dec 10 '25 |
Option Exercise |
0.00 |
1,196 |
0 |
10,670 |
| Gharib Samir M. | PRESIDENT AND CFO |
Oct 20 '25 |
Option Exercise |
0.00 |
2,053 |
0 |
6,727 |
| Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER |
Oct 20 '25 |
Option Exercise |
0.00 |
4,784 |
0 |
11,013 |
| Parkman Healthcare Partners LL | 10% Owner |
Oct 06 '25 |
Buy |
17.91 |
256 |
4,585 |
1,307 |
| Parkman Healthcare Partners LL | 10% Owner |
Oct 06 '25 |
Sale |
19.14 |
257 |
4,920 |
1,050 |
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):